"2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine"@en . . . "95%"@en . . . "Humans and other mammals"@en . . "Mellaril-S"@en . . . . "Mellerette"@en . . " "@en . . . . "50-52-2"@en . "Sonapax"@en . . . . . " "@en . "Mallorol"@en . . . . "Thioridazinum"@en . . "60%"@en . "approved"@en . . . "Meleril"@en . . . "Tioridazina"@en . . "Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis."@en . . . "Melleril"@en . . . "LD₅₀=956-1034 mg/kg (Orally in rats); Agitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock"@en . . . . . . . . . . . . "3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine"@en . "Malloryl"@en . . . . . "For the treatment of schizophrenia and generalized anxiety disorder."@en . . . . "Thioridazin"@en . . . . . . . . . "Thioridazine"@en . "Mellerets"@en . . . "21-25 hours"@en . . . . "A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618)"@en . . . . . . "Mellaril"@en . . . . . . . . . . "10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine"@en . . "Orsanil"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .